Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Is there role of Her2 directed therapy in adjuvant treatment of colon adenocarcinoma for tumors that are HER2 3+ by IHC
Related Questions
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
What treatment sequence do you follow for patients with rectal cancer who are candidates for both PROSPECT and TNT/Watch and wait?
Would you consider the use of avapritinib in advanced GIST after failure of imatinib, sunitinib and ripretinib in exon 11 and 17 kit mutated GIST?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
What is your approach for adjuvant chemotherapy for a patient with colon adenocarcinoma, pMMR, T2 with 3 positive lymph nodes and 2 pericolic adipose tumor deposits?
After neoadjuvant Nivolumab/Ipilimumab x4, do you offer adjuvant Nivolumab in the adjuvant setting for oligometastatic MSI-high colon cancer in a patient who achieved CR?
How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?
What systemic therapy would you use in T3N1M1 MMR proficient rectal cancer with solitary liver lesion when going for curative intent (chemo>short course RT> resection of primary and liver met)?
